Cannara Biotech (TSE:LOVE)
TSX:LOVE
Want to see TSE:LOVE full AI Analyst Report?
LOVE Stock Chart & Stats
C$1.83
C$0.03(3.90%)
At close: 4:00 PM EST
C$1.83
C$0.03(3.90%)
Day’s Range― - ―
52-Week RangeC$1.08 - C$2.07
Previous CloseN/A
Volume7.64K
Average Volume (3M)45.69K
Market Cap
C$175.83M
Enterprise ValueC$193.18M
Total Cash (Recent Filing)C$16.52M
Total Debt (Recent Filing)C$34.85M
Price to Earnings (P/E)37.0
Beta0.31
Next Earnings
Jul 29, 2026EPS Estimate
0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding98,782,150
10 Day Avg. Volume37,006
30 Day Avg. Volume45,690
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.64
Price to Sales (P/S)1.57
P/FCF Ratio12.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.08Price Target Upside68.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.15
Revenue Forecast (FY)C$127.58M
Bulls Say, Bears Say
Bulls Say
Cost Structure And Capacity AlignmentLow-cost production facilities and a disciplined rollout of processing capacity at Valleyfield align supply with demand and enable competitive pricing flexibility.
Market Share ExpansionExpanding share in Quebec combined with growing national distribution suggests revenue growth can be driven from a solid regional foothold and customer loyalty.
ProfitabilityStrong gross margins and a consistent record of positive operating cash flow point to durable profitability that could underpin higher valuation multiples.
Bears Say
Earnings Visibility And Guidance RiskA revenue miss driven by seasonal effects and launch normalization increases the risk of guidance revisions and could pressure the stock multiple if expectations are reduced.
Post-launch Sales NormalizationNormalization of sales after an initially strong product launch can weaken near-term revenue growth and slow momentum for new product categories.
Seasonality And Revenue VolatilitySeasonal provincial purchasing patterns create revenue volatility that may complicate quarter-to-quarter comparisons and investor expectations.
Cannara Biotech News
LOVE FAQ
What was Cannara Biotech’s price range in the past 12 months?
Cannara Biotech lowest stock price was C$1.08 and its highest was C$2.07 in the past 12 months.
What is Cannara Biotech’s market cap?
Cannara Biotech’s market cap is C$175.83M.
When is Cannara Biotech’s upcoming earnings report date?
Cannara Biotech’s upcoming earnings report date is Jul 29, 2026 which is in 91 days.
How were Cannara Biotech’s earnings last quarter?
Cannara Biotech released its earnings results on Apr 14, 2026. The company reported C$0.02 earnings per share for the quarter, missing the consensus estimate of C$0.05 by -C$0.03.
Is Cannara Biotech overvalued?
According to Wall Street analysts Cannara Biotech’s price is currently Undervalued.
Does Cannara Biotech pay dividends?
Cannara Biotech does not currently pay dividends.
What is Cannara Biotech’s EPS estimate?
Cannara Biotech’s EPS estimate is 0.05.
How many shares outstanding does Cannara Biotech have?
Cannara Biotech has 98,782,150 shares outstanding.
What happened to Cannara Biotech’s price movement after its last earnings report?
Cannara Biotech reported an EPS of C$0.02 in its last earnings report, missing expectations of C$0.05. Following the earnings report the stock price went down -6.341%.
Which hedge fund is a major shareholder of Cannara Biotech?
Currently, no hedge funds are holding shares in TSE:LOVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cannara Biotech
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-derivative products in Canada. The company operates in two segment Cannabis operations and Real estate operations. It offers its products under TRIBAL, nugz, and ORCHID CBD brand name. The company sells its products through wholesalers and online merchandisers. In addition, it engages in the real estate operations. Cannara Biotech Inc. was incorporated in 2017 and is headquartered in Saint-Laurent, Canada.
LOVE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a strong financial performance with record-breaking metrics and significant market share growth in key regions and product categories. However, there are challenges in maintaining market share in certain regions and managing cash flow effectively.View all TSE:LOVE earnings summariesLOVE Stock 12 Month Forecast
Average Price Target
C$3.08
▲(68.49% Upside)
Technical Analysis
Jushi Holdings
―
Organigram Global
―
Auxly Cannabis Group
―
Cannabist Company Holdings
―
Grown Rogue International
―
Options Prices
Currently, No data available
---